IgA nephropathy (IgAN), or Berger’s disease, is a kidney condition that occurs when abnormal immunoglobulin A (IgA) antibodies trigger inflammation in the kidneys. Until recently, treatment for IgAN ...

IgA nephropathy (IgAN) is a kidney condition where antibodies (immune system proteins) build up and cause damage in your kidneys. IgAN, also known as Berger’s disease, does not have a cure. However, ...

The global N-(n-propyl) thiophosphoric triamide (NPPT) urease inhibitor market is experiencing rapid expansion as agricultural producers seek to improve nitrogen use efficiency, reduce ...

Please provide your email address to receive an email when new articles are posted on . Iptacopan received traditional FDA approval for treating adults with immunoglobulin A nephropathy. The ...

The Food and Drug Administration on Thursday approved a new cholesterol pill from Merck that works in a different way from statins. The daily pill, called Lipfendra, is known as a PCSK9 inhibitor — a ...

East Hanover, July 16, 2026 – Novartis today announced that the US Food and Drug Administration (FDA) has granted traditional approval for Fabhalta ® (iptacopan) to slow kidney function decline in ...

Montreal, July 13, 2026 – Novartis Pharmaceuticals Canada Inc. (“Novartis Canada”) announced today that Health Canada has granted approval for VANRAFIA TM (atrasentan tablets) for proteinuria ...

Trials of current B cell-directed therapies and an investigational inhibitor of the alternative complement pathway demonstrate proteinuria reduction in patients with IgA nephropathy. Targeting ...

Trutakna (atacicept-vymj), a first-in-class dual BAFF and APRIL inhibitor, secured FDA accelerated approval to reduce proteinuria in adults with primary IgA nephropathy, supported by data ...